Try our beta test site
7 studies found for:    Mocetinostat | lymphoma OR CLL
Show Display Options
Rank Status Study
1 Recruiting Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Mocetinostat Plus Brentuximab Vedotin
2 Completed Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Condition: Lymphoma
Intervention: Drug: MGCD0103
3 Terminated Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
4 Recruiting Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Conditions: Lymphoma;   Relapsed and Refractory;   Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Intervention: Drug: Mocetinostat
5 Completed Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Tumors;   Non Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
6 Terminated MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
Intervention: Drug: MGCD0103 and Azacitidine
7 Completed A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Intervention: Drug: MGCD0103

Study has passed its completion date and status has not been verified in more than two years.